AQST Stock Analysis: Buy, Sell, or Hold?
AQST - Aquestive Therapeutics, Inc. Common Stock
$4.73
0.60 (14.53%)
▲
5d:
+11.82%
30d:
+11.56%
90d:
+26.13%
HOLD
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Smart Money Distribution
AQST is up 5.8% this week, but smart money is buying puts. Top strike: $4 2026-06-18 with 1,485 OI. Put ratio: 70% View Scanner →
Strength: 4.9/10
Get Alerted When AQST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called AQST this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: AQST is 9.2% above its trading range ($4.33). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: AQST is 9.2% above its trading range ($4.33). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: AQST is currently trading at $4.73, which is considered extended relative to its 30-day fair value range of $4.07 to $4.33.
Technical Outlook: Technically, AQST is in a strong uptrend. Immediate support is located at $4.10, while resistance sits at $5.02. The stock is showing strong short-term momentum, up 14.5% recently.
Market Sentiment: AQST has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.89 (+87.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AQST is in a strong uptrend. Immediate support is located at $4.10, while resistance sits at $5.02. The stock is showing strong short-term momentum, up 14.5% recently.
Market Sentiment: AQST has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.89 (+87.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.07 -
$4.33
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+9.2% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.5%)
- BULLISH: Trading 87.9% below Wall St target ($8.89)
- CAUTION: Extended 9.2% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$4.07 -
$4.33
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.10
Resistance Level
$5.02
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.16
Wall Street Target
$8.89
(+87.9%)
Revenue Growth (YoY)
9.7%
Profit Margin
-188.1%
Share & Embed Analysis
Last updated: May 14, 2026 6:54 PM ET
Data refreshes hourly during market hours. Next update: 7:54 PM
Data refreshes hourly during market hours. Next update: 7:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AQST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
A Ernest Toth Jr
SELL
58254 shares
2026-03-10
Cassie Jung
SELL
45791 shares
2026-03-10
Daniel Barber
SELL
180677 shares
2026-03-10
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$40 | 57 HOLD |
